Interaction among 5,10 methylenetetrahydrofolate reductase, plasminogen activator inhibitor and endothelial nitric oxide synthase gene polymorphisms predicts the severity of coronary artery disease in Turkish patients

Coronary Artery Disease

Volumn 17, Issue 5, 2006, Pages 413-417

  Agirbasli, Deniz ^a   Agirbasli, Mehmet ^a,d   Williams, Scott M ^b   Phillips III, John A ^c  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d Fenerbahce Kadikoy   (Turkey)

Author keywords

5,10 methylenetetrahydrofolate reductase C677T; Coronary artery disease; Multifactor dimensionality reduction; Nitric oxide synthase 3 27; Plasminogen activator inhibitor 4G 5G

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BIOLOGICAL MARKER; DNA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BASE PAIRING; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CONTROL GROUP; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE MARKER; DISEASE SEVERITY; EVALUATION; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC MODEL; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MOLECULAR INTERACTION; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RISK FACTOR; SAMPLE; STANDARD; TANDEM REPEAT; TURKEY (REPUBLIC);

ALLELES; CASE-CONTROL STUDIES; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; ENDOTHELIUM, VASCULAR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE (NAD+); MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS; TURKEY;

EID: 33748178186     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200608000-00003     Document Type: Article

References (33)

1. Nordlie MA, Wold LE, Kloner RA. Genetic contributors toward increased risk for ischemic heart disease. J Mol Cell Cardiol 2005; 39:667-679.
2. Watson KE, Topol EJ. Pathobiology of atherosclerosis: are there racial and ethnic differences? Rev Cardiovasc Med 2004; 5 (suppl 3):S14-S21.
3. Ignarro LJ, Napoli C. Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis. Curr Atheroscler Rep 2004; 6:281-287.
4. Gauthier GM, Keevil JG, McBride PE. The association of homocysteine and coronary artery disease. Clin Cardiol 2003; 26:563-568.
5. Agirbasli M. Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int J Clin Pract 2005; 59:102-106.
6. Margaglione M, Capucci G, d'Addedda M, Colaizzo D, Giuliani N, Vecchione G, et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscl Thromb Vasc Biol 1998; 18:562-567.
7. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98:2241-2247.
8. Mikkelsson J, Perola M, Wartiovaara U, Peltonen L, Palotie A, Penttila A, et al. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle aged Finnish men who died suddenly. Thromb Haemost 2000; 84:78-82.
9. Nordenhem A, Wiman B. Plasminogen activation inhibitor-1 (PAI-1) content in platelets from healthy individuals genotyped for the 4G/5G polymorphism in the PAI-1 gene. Scand J Clin Lab Invest 1997; 57:453-461.
10. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen activator inhibitor-1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92:1851-1855.
11. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variations at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasminogen activator inhibitor-1 activity. Arterioscl Thromb 1991; 11:183-190.
12. Blom HJ. Genetic determinants of hyperhomocysteinaemia: the roles of cystathionine beta-synthase and 5,10-methylenetetrahydrofolate reductase. Eur J Pediatr 2000; 159 (suppl 3):S208-S212.
13. Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HUGE review. Am J Epidemiol 2000; 151:862-877.
14. Lusis AJ, Fogelman AM, Fonarow GC. Genetic basis of atherosclerosis: Part II clinical implications. Circulation 2004; 110:2066-2071.
15. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG; MTHFR Studies Collaboration Group. MTHFR 677C→T polymorphism and risk of coronary artery disease: a meta analysis. JAMA 2002; 288:2023-2031.
16. Almawi WY, Ameen G, Tamim H, Finan RR, Irani-Hakime N. Factor V G1691A, prothrombin G20210A, and methylenetetrahydrofolate reductase [MTHFR] C677T gene polymorphism in angiographically documented coronary artery disease. J Thromb Thrombolysis 2004; 17:199-205.
17. Xu H, Chen Z, Tang J. Genetic polymorphisms of homocysteine metabolism related enzymes in patients with coronary heart disease. Zhonghua Yi Xue Za Zhi 1999; 79:414-416.
18. Izumi M, Iwai N, Ohmichi N, Nakamura Y, Shimoike H, Kinoshita M. Molecular variant of 5,10-methylenetetrahydrofolate reductase is a risk factor of ischemic heart disease in the Japanese population. Atherosclerosis 1996; 121:293-294.
19. Gulec S, Aras O, Akar E, Tutar E, Omurlu K, Avci F, et al. Methylene tetrahydrofolate reductase gene polymorphism and the risk of premature myocardial infarction. Clin Cardiol 2001; 24:281-284.
20. Mager A, Lalezari S, Shohat T, Birnbaum Y, Adler Y, Magal N, Shohat M. Methylenetetrahydrofolate reductase genotypes and early-onset coronary artery disease. Circulation 1999; 100:2406-2410.
21. Anderson TJ. Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail Rev 2003; 8:71-86.
22. Wang XL, Sim AS, Wang MX, Murrell GA, Trudinger B, Wang J. Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity. FEBS Lett 2000; 471:45-50.
23. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylene tetrahydrofolate reductase. Nat Genet 1995; 10:111-113.
24. Rossaak JI, Van Rij AM, Jones GT, Harris EL. Association of the 4G/5G polymorphism in the promoter region of the plasminogen activator inhibitor-1 with abdominal aortic aneurysms. J Vasc Surg 2000; 31:1026-1032.
25. Wang LX, Sim AS, Badenhop RF, McCredie RM, Wilcken DE. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med 1996; 2:41-45.
26. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, et al. Multifactor dimensionality reduction reveals high-order interactions among estrogen metabolism genes in sporadic breast cancer. Am J Hum Genet 2001; 69:138-147.
27. Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 2003; 19:376-382.
28. Weir BS. Genetic data analysis II. Sunderland, MA: Sinauer Associates; 1996.
29. Lewis PO, Zaykin D. Genetic data analysis Version 1.0 (d12). Free computer program for the analysis of allelic data distributed by the authors over the Internet from the GDA home page at http://alleyn.eeb.uconn.edu/gda/ ;1999.
30. Zhao JH, Curtis D, Sham PC. Model free analysis and permutation test for allelic associations. Hum Hered 2000; 50:133-139.
31. Brzustowics LM, Merette J, Xie X, Townsend L, Gilla TC, Ott J. Molecular and statistical approaches to the detection and correction of errors in genotype databases. Am J Hum Genet 1993; 53:1137-1145.
32. Williams SM, Addy JH, Phillips JA 3rd, Dai M, Kpodonu J, Afful J, et al. Combinations of variations in multiple genes are associated with hypertension. Hypertension 2000; 36:2-6.
33. Williams SM, Ritchie MD, Phillips JA 3rd, Dawson E, Prince M, Dzhura E, et al. Multilocus analysis of hypertension: a hierarchical approach. Hum Hered 2004; 57:28-38.